Sustained release OTX-TP reduces IOP in phase 2b clinical trial

Ocular Therapeutix announced that sustained release OTX-TP achieved “clinically meaningful” reduction in IOP in its phase 2b study, according to a press release reporting topline results.OTX-TP (sustained release travoprost) is intended for treatment of glaucoma and ocular hypertension.